The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Congresses
Oral
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Breast Cancer
A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P)
Yeon Hee Park
View presentation
Poster
Pipeline Compounds
ASCO 2026 | May 29 - June 2, 2026
Other/Multi
A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist antibody–drug conjugate,in patients with advanced/metastatic solid tumors
Shigehiro Koganemaru
View presentation
Poster
Pipeline Compounds
ASCO 2026 | May 29 - June 2, 2026
Other/Multi
A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced/metastatic solid tumors (Parts 1 and 2)
Shiraj Sen
View presentation
Poster
Pipeline Compounds
ASCO 2026 | May 29 - June 2, 2026
Genitourinary Cancers
A phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced/metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer
Manish R. Patel
View presentation
Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Tumor-agnostic
A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 immunohistochemistry 3+ solid tumors: DESTINY-PanTumor04
Bradley J. Monk
View presentation
Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Gastric Cancer
Additional health-related quality of life analysis from DESTINY-Gastric04, a randomized phase 3 study of trastuzumab deruxtecan vs ramucirumab + paclitaxel in patients with human epidermal growth factor receptor 2-positive unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma
Kohei Shitara
View presentation
Poster
R-DXd
ASCO 2026 | May 29 - June 2, 2026
Gynecologic Cancers
Exposure–response analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed antibody–drug conjugate, to inform dose selection for phase 3 development in platinum-resistant ovarian cancer
Felipe K. Hurtado
View presentation
Oral
Dato-DXd
ASCO 2026 | May 29 - June 2, 2026
Breast Cancer
First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whome immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study
David W. Cesco
View presentation
Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Gastric Cancer
First-line trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2‑expressing gastric cancer, gastroesophageal junction adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: Safety results from DESTINY-Gastric03 part 2 arms D and F, and Part 4
Yelena Y. Janjigian
View presentation
Poster
HER3-DXd
ASCO 2026 | May 29 - June 2, 2026
Breast Cancer
HERTHENA-Breast04: A phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician's choice in hormone receptor-positive/human epidermal growth factor receptor 2-negative unresectable locally advanced or metastatic breast cancer
Barbara Pistilli
View presentation
Pages: 1  2  3  
Connect with an MSL
Linkedin Icon Twitter Icon

©2026  Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24